# A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

> **NCT07288957** · PHASE1 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 266 (estimated)

## Conditions studied

- Solid Tumors (Phase 1)

## Interventions

- **DRUG:** ABSK131

## Key facts

- **NCT ID:** NCT07288957
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288957, "A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07288957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*